— Are you looking for the complete & verified bond data?

— We have everything you need:

full data on over 900 000 bonds, 80 000 stocks, 116 000 ETF & Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.

Why

You will have detailed descriptive & pricing data for 650K bonds, 76K stocks, 8K ETFs

Get full access to the platform from any device & via Cbonds app

Enhance your portfolio management with Cbonds Excel Add-in

Build yield maps, make chart comparison within a click

Don't wait any longer — start using Cbonds today! Register

“Shandong Pharmaceutical Glass Co., Ltd.”Announcement on Diluted Immediate Return, Mitigating Immediate Measures, and Related Entity Commitments for Issuance of A-shares to Specific Objects in 2026

January 14, 2026 SSE

Show full article

This functionality is available for registred users only

Issuer — Shandong Pharmaceutical Glass

Full name

Shandong Pharmaceutical Glass Co Ltd
Industry

Packaging
М/S&P/F

*** / *** / ***

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

Evaluate advanced analytical tools
Get full online access to the database
Try our powerful bond screener
Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Other Company's News

Try in 7-days Trial access

Free for company representative

Get full online access to the database
Use our powerful bond screener
Track bond prices from 400+ sources
Smart Portfolio Monitoring
Evaluate advanced analytical tools

Why Cbonds?

24 Years of Market Leadership
Trusted by clients across 90 countries for decades of reliable service
Used by Financial Professionals & Fintech central banks, asset managers, fintech innovators
Convenient platform for private investors for informed investment decisions